Advances with pharmacotherapy for peritoneal metastasis
| Autor: | Shouzou Sako, Nobuyuki Takao, Yang Liu, Shunsuke Motoi, Yutaka Yonemura, Yasuyuki Kamada, Haruaki Iahibashi, Akiyoshi Mizumoto, Satoshi Wakama, Masumi Ichinose, Kazurou Nishihara |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Peritoneal metastasis
medicine.medical_specialty Peritoneal surface medicine.medical_treatment Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Peritonectomy medicine Humans Pharmacology (medical) Peritoneal Neoplasms Pharmacology Clinical Trials as Topic Chemotherapy business.industry Cytoreduction Surgical Procedures Hyperthermia Induced General Medicine Perioperative Combined Modality Therapy Survival Analysis Surgery Chemotherapy Cancer Regional Perfusion 030220 oncology & carcinogenesis Treatment strategy Female Peritoneum Cytoreductive surgery business 030217 neurology & neurosurgery |
| Zdroj: | Expert Opinion on Pharmacotherapy. 21:2057-2066 |
| ISSN: | 1744-7666 1465-6566 |
| Popis: | A new treatment strategy involving cytoreductive surgery (CRS) combined with perioperative intraperitoneal (IP) chemotherapy was proposed in 1999 by the Peritoneal Surface Oncology Group International, and the strategy is now justified as a state-of-the-art treatment to improve the long-term survival of patients with peritoneal metastasis (PM). To achieve cure in the patients with PM, complete removal of macroscopic tumors and eradication of micrometastasis on the peritoneum, left after CRS are essential. Systemic chemotherapy is not indicated for the treatment of PM. In contrast, intraperitoneal (IP) chemotherapy brings about significantly higher locoregional dose intensity in the peritoneal cavity and subperitoneal tissues. In combination with anticancer drugs, hyperthermia enhances cytotoxicity against cancer cells.This article provides a systematic overview of PM from various cancers including gastric, colorectal, small bowel, appendiceal cancer, and mesothelioma. It also includes all the essential aspects of therapy.CRS plus perioperative intraperitoneal chemotherapy is safe with acceptable morbidity and mortality. It is justified as a standard treatment to improve the long-term survival of patients with PM and is now performed with curative intent for PM from various malignancies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|